2018
DOI: 10.31557/apjcp.2018.19.11.3187
|View full text |Cite
|
Sign up to set email alerts
|

CD56 and CD11b Positivity with Low Smac/DIABLO Expression as Predictors of Chemoresistance in Acute Myeloid Leukaemia: Flow Cytometric Analysis

Abstract: Background:Resistance to chemotherapy is a major obstacle to curing acute myeloid leukaemia (AML), and several antigens are claimed to play primary roles in this resistance.Purpose:The aim of this study was to evaluate the roles of CD56, CD11b and Smac/DIABLO gene expression levels as prognostic markers of the clinical outcome, response to chemotherapy and survival of AML patients.Materials and Methods:A cross-sectional observational study was conducted on 60 naïve-AML patients who received induction therapy w… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

1
11
0

Year Published

2019
2019
2024
2024

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(12 citation statements)
references
References 31 publications
1
11
0
Order By: Relevance
“…Resistance to chemotherapy is a major obstacle in AML therapy. High ITGAM/CD56 co-expression combined with low Smac/DIABLO expression were proposed to be an important predictor of chemoresistance in AML patients [77]. The prognostic value of ITGAM in AML patients has been extensively assessed, and a correlation between high ITGAM expression and poor prognosis in AML has been established [51, 78].…”
Section: Discussionmentioning
confidence: 99%
“…Resistance to chemotherapy is a major obstacle in AML therapy. High ITGAM/CD56 co-expression combined with low Smac/DIABLO expression were proposed to be an important predictor of chemoresistance in AML patients [77]. The prognostic value of ITGAM in AML patients has been extensively assessed, and a correlation between high ITGAM expression and poor prognosis in AML has been established [51, 78].…”
Section: Discussionmentioning
confidence: 99%
“…However, mechanical hallmarks of macrophages remain independent of adhesion once differentiation was reached. CD11b has been reported as a key biomarker in immune cells for the progression of diseases like cancer and autoimmunity 25,[28][29][30][91][92][93] . Given the growing evidence that cell elasticity and fluidity suffer alterations in disease, adhesion and mechanics of immune cells may appear as relevant biomarkers 26,[94][95][96][97][98][99][100][101][102][103] .…”
Section: Discussionmentioning
confidence: 99%
“…This integrin binds to multiple extracellular matrix (ECM) and vascular proteins, like fibrinogen and ICAM-1, and is commonly used as a marker for macrophage differentiation 8,24,25 . CD11b is also known to be a therapeutic target for other diseases like Lupus, and various types of cancer and has been used as a prognosis marker in myeloid leukemia [25][26][27][28][29] . Importantly, CD11b regulates macrophage polarization 30 .…”
Section: Introductionmentioning
confidence: 99%
“…Therefore CD11b is required for the interaction of leukemic cells in the bone marrow microenvironment. It also suppresses the immune system and is a marker for myeloidderived suppressor cells that play a role in the progression of malignancies 22,23 25 . This finding might be a clue of altered hemostasis and coagulation tests we found in CD11b positive AML patients.…”
Section: Patient Characteristicsmentioning
confidence: 99%